Oncologix Tech Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCLG research report →
Price Chart
About the company
Oncologix Tech, Inc. is a biopharmaceutical company whose main products include DNAGO and genomego which provides clinical genetic testing on all 20,000+ genes encompassing over 7,000 rare genetic diseases. It also previously operated in personal home care services and the manufacturing and distribution of medical technologies.
- CEO
- Michael A. Kramarz
- IPO
- 1995
- Employees
- 191
- HQ
- Lafayette, LA, US
Get TickerSpark's AI analysis on OCLG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $73.66K
- P/E
- -0.03
- PEG
- -0.00
- P/S
- 0.03
- P/B
- 0.04
- EV/EBITDA
- -0.07
- Div Yield
- 0.00%
- Gross Margin
- 20.05%
- Op Margin
- -30.35%
- Net Margin
- -83.19%
- ROE
- 94.77%
- ROIC
- 0.00%
Latest fiscal year · YoY change
- Revenue
- $2.85M+0.0%
- Gross Profit
- $571.56K+0.0%
- Op Income
- $-865,000
- Net Income
- $-2,371,000+0.0%
- EPS
- $-0.00+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.00
- RSI (14)
- 52
- Avg Volume
- 15.98K
No earnings-call transcripts are available for OCLG yet.
- Free Float
- 100.0%
- Shares Outstanding
- 736.62M
- Float Shares
- 736.62M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 31, 13 | HART VICKIE | other | 1,600,000 |
| Dec 31, 13 | Erwin Roy Wayne | other | 10,000 |
| Dec 31, 13 | Erwin Roy Wayne | other | 2,400,000 |
| Dec 31, 13 | Kramarz Michael Anthony | other | 2,100,000 |
| Dec 31, 13 | Griffith Barry K | other | 10,000 |
| Dec 30, 13 | HART VICKIE | other | 0 |
| Sep 12, 13 | Schreifels Donald | buy | 1,500,000 |
| Sep 12, 13 | Schreifels Donald | other | 1,500,000 |
| Aug 6, 13 | Schreifels Donald | other | 0 |
| Aug 8, 13 | Schreifels Donald | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OCLG coverage
Recent articles, reports, and earnings notes.
No research on OCLG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OCLG report →